Grifols signs an agreement with Cumberland Pharmaceuticals to market ibuprofen for intravenous infusion
- Grifols will have exclusive commercial rights to the drug, indicated for the treatment of mild to moderate postoperative pain and fever, in Spain, Portugal, Argentina, Chile, Brazil, Ecuador, Peru and Uruguay.
Barcelona, October 9, 2013 – Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), the third manufacturer in the world of plasma-based biological medicines, hospital pharmacy products and diagnostic technologies for clinical use, has signed a licensing agreement for the ibuprofen for intravenous infusion with Cumberland Pharmaceuticals (NASDAQ: CPIX), a US pharmaceutical company specializing in the areas of acutecare and gastroenterology that manufactures and markets the product under the brand name Caldolor®.
The terms of the agreement allow Grifols to commercialize the drug in Spain and Portugal, as well as in the other Latin American countries where it has obtained the license. Argentina, Chile, Brazil, Ecuador, Peru and Uruguay.
With the signing of this agreement, Grifols strengthens the international growth strategy of the Hospital Division, optimizes the sales network in the countries where it has obtained the license and expands its portfolio of intravenous solutions.
Caldolor® is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor®(ibuprofen) Injection, the first injectable treatment for pain and fever available in the United States; and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit the company website at www.cumberlandpharma.com
Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.
As a leading producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.
In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com